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http://dx.doi.org/10.1016/j.ccell.2015.09.021SUMMARYTumorigenesis is associated with increased glucose consumption and lipogenesis, but how these pathways
are interlinked is unclear. Here, we delineate a pathway in which EGFR signaling, by increasing glucose
uptake, promotes N-glycosylation of sterol regulatory element-binding protein (SREBP) cleavage-activating
protein (SCAP) and consequent activation of SREBP-1, an ER-bound transcription factor with central roles in
lipidmetabolism. Glycosylation stabilizes SCAP and reduces its association with Insig-1, allowingmovement
of SCAP/SREBP to the Golgi and consequent proteolytic activation of SREBP. Xenograft studies reveal that
blocking SCAP N-glycosylation ameliorates EGFRvIII-driven glioblastoma growth. Thus, SCAP acts as key
glucose-responsive protein linking oncogenic signaling and fuel availability to SREBP-dependent lipogen-
esis. Targeting SCAP N-glycosylation may provide a promising means of treating malignancies and meta-
bolic diseases.INTRODUCTION
Elevated lipogenesis is a common patho-physiological charac-
teristic of cancer and metabolic diseases (Guo et al., 2013;
Menendez and Lupu, 2007; Moon et al., 2012; Ru et al., 2013;
Tang et al., 2011). In these processes, a critical regulatory role
is played by sterol regulatory element-binding proteins
(SREBPs), a family of transcription factors that control the
expression of genes important for the uptake and synthesis of
cholesterol, fatty acids, and phospholipids (Goldstein et al.,
2006; Jeon and Osborne, 2012; Nohturfft and Zhang, 2009).
There are two mammalian SREBP genes, SREBF1 and SREBF2.
SREBP-1a and -1c, which are encoded bySREBF1with different
N terminus (20 amino acids) owing to their mRNAs being tran-Significance
Twenty years ago, Nobel Laureates Brown & Goldstein discov
They revealed that sterols modulate Insig interaction with SCAP
ditions. Our study identifies glucose as an indispensible comp
rols is insufficient to initiate SCAP/SREBP trafficking and SRE
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that SCAP acts as a key glucose-responsible protein to integra
metabolism and tumor growth.
Cascribed from different transcriptional start sites, mainly regulate
the expression of genes required for fatty acid synthesis.
SREBP-2 is encoded by SREBF2 and is responsible for the
synthesis of cholesterol (Goldstein et al., 2006; Horton et al.,
2002, 2003). Recent evidence shows that the nuclear form of
SREBP-1 is highly upregulated in a variety of malignancies (Et-
tinger et al., 2004; Guo et al., 2009b; Li et al., 2014). Targeting
SREBP-1 has become a promising therapeutic strategy to treat
cancer and other metabolic syndromes (Griffiths et al., 2013;
Guo et al., 2014; Kamisuki et al., 2009; Tang et al., 2011).
SREBP-1 and SREBP-2 are synthesized as inactive precur-
sors bound to the membrane of the ER through two trans-
membrane domains (Goldstein et al., 2006). SREBP activation
requires proteolytic release of an N-terminal fragment thatered SREBPs as key proteins that regulate lipid metabolism.
/SREBP to inhibit SREBP function under physiological con-
onent of SREBP function. Without glucose, reduction of ste-
BP activation. Glucose-mediated N-glycosylation of SCAP
and the subsequent lipogenic function of SREBP. We show
te oncogenic signaling and fuel availability for control of lipid
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constitutes a basic helix-loop-helix transcription factor (Gold-
stein et al., 2006; Wang et al., 1994). Currently, post-translational
activation of SREBPs is best understood in the context of cellular
cholesterol homeostasis (Radhakrishnan et al., 2008; Sun et al.,
2007). When cholesterol level is high, it binds to SREBP-cleav-
age activating protein (SCAP), inducing a conformational change
that promotes binding to ER-anchored insulin induced gene pro-
tein (Insig), thus preventing Golgi transport and activation of
SREBPs (Adams et al., 2004; Sun et al., 2007; Yang et al.,
2002). When the cholesterol concentration drops, the SCAP/
SREBP complex dissociates from Insig, allowing vesicular trans-
port to the Golgi where SREBPs are exposed to proteases that
release the transcriptionally active N-terminal fragment (Gold-
stein et al., 2006; Nohturfft et al., 2000; Sun et al., 2007).
Glucose is a major resource for de novo lipid synthesis. In can-
cer cells, elevated glucose consumption is often accompanied
by increased lipogenesis (Guo et al., 2013; Menendez and
Lupu, 2007), and the link between glucose supply and SREBP-1
activation seems common in both physiological and patho-
physiological conditions (Guillet-Deniau et al., 2004; Hasty
et al., 2000; Horton et al., 1998; Kaplan et al., 2008). In a previous
study, we showed that epidermal growth factor receptor (EGFR)
via PI3K/Akt signaling activated SREBP-1 in glioblastoma (GBM)
cells (Guo et al., 2009b, 2011). While a number of studies have
demonstrated that elevated EGFR signaling is coupled with
enhanced glucose uptake and lipogenesis in tumorigenesis (Ba-
bic et al., 2013; Cloughesy et al., 2014; Guo et al., 2009a, 2009b),
the molecular mechanisms that underlie the crosstalk between
the altered glucose and lipid metabolism in tumorigenesis
remain largely unknown. In this study, we test the hypothesis
that SCAP acts as a key glucose-responsive protein to integrate
oncogenic signaling and fuel availability for modulation of
SREBP-dependent lipogenesis.
RESULTS
Glucose Activates SREBPs via Upregulation of SCAP
To investigate how glucose and sterol signaling are integrated
during SREBP activation, human GBM U87 cells that have
been shown to contain a high SREBP-1 activity (Guo et al.,
2009b, 2011) were grown in the absence or presence of glucose
and sterols (cholesterol/25-hydroxycholesterol) and SREBP pro-
cessing was analyzed by western blot and immunofluorescence
microscopy. We found that in the absence of glucose, only the
ER-bound SREBP-1 precursor could be clearly detected, even
in cells that were deprived of sterols by removal of serum (Fig-
ure 1A). While glucose supplement modestly activated SREBP-1
in the presence of sterols (as assessed by the appearance of the
N-terminal cleavage fragment of SREBP-1), maximal SREBP-1
and SREBP-2 cleavage required both glucose supplement and
low sterols in the absence or presence of serum (Figures 1A
and S1A). Moreover, glucose activated SREBP-1 and SREBP-2
in a dose- and time-dependentmanner and increased the protein
levels of fatty acid synthase (FASN) and low-density lipoprotein
receptor (LDLR), the genes encoding both of which are down-
stream targets for SREBP-1 (Figures 1B, 1C,S1A, andS1B) (Ben-
nett et al., 1995; Yokoyama et al., 1993). Furthermore, real-time
quantitative (q)PCR analysis showed that glucose stimulation
enhanced both SREBP-1a and -1c expression and activated570 Cancer Cell 28, 569–581, November 9, 2015 ª2015 Elsevier Inc.the expression of SREBP-1 or SREBP-2 regulated genes
involved in lipid metabolism (Figure S1C). Using confocal fluo-
rescence imaging, we found that stimulation of U87 cells with
glucose promoted nuclear translocation of transgenic GFP-
SREBP-1 (Figures 1D and S1D). Translocation of endogenous
SREBP-1 into the nucleus in response to glucose stimulation
was demonstrated by immunofluorescence (Figures 1E and
S1E). In contrast, under glucose-deprived conditions, even with
removal of sterols, SREBP-1 was still retained in the ER mem-
brane as shown by its co-staining with protein disulfide isom-
erase (PDI), an ER membrane protein (Figures 1E and S1E)
(Uehara et al., 2006). These data suggest that glucose is required
for SREBP activation under conditions of sterol deprivation.
SREBP stability, transport to the Golgi, and cleavage require
formation of a complex between SREBP and SCAP (Nohturfft
et al., 2000; Rawson et al., 1999; Sakai et al., 1998). We found
that glucose-induced cleavages of SREBP-1 and SREBP-2
were accompanied by an increase of SCAP protein levels in
GBM cells (Figures 1F, S1A, and S1B). Similar results were
observed in various other cancer cell lines in which both
SREBP-1 and -2 were activated (see Figure S1F). HEK293T cells
expressing GFP-SCAP and full length FLAG-SREBP-1a, -1c,
or HA-SREBP-2 displayed glucose-dependent upregulation of
GFP-SCAP and activation of all three SREBP isoforms, which
were detected by increased N-terminal fragment of epitope-
tagged SREBP in the nuclear fraction under conditions of
glucose supplement (Figures 1G and S1G). We found that
knock down of SCAP reduced glucose-mediated activation of
SREBP-1 and SREBP-2 (Figure 1H).
Because liver X receptor (LXR), a member of the nuclear re-
ceptor family of transcription factors, promotes the expression
of SREBP-1c upon activation (Repa et al., 2000), and glucose
is reported to activate LXR in hepatocytes (Mitro et al., 2007),
we sought to examine whether LXR possibly involves in
glucose-activated SCAP/SREBP signaling. As shown in Figures
S1A–S1C, our data show that both the protein and mRNA levels
of ATP-binding cassette activating proteins ABCA1 and ABCG1,
which are major downstream targets of LXR (Zelcer and Tonto-
noz, 2006), were not significantly upregulated by glucose sup-
plement in U87 cells within 12 hr, demonstrating that LXR was
not strongly activated by glucose in GBM cells. In contrast,
SCAP protein and SREBP-1 and SREBP-2 cleavage were
enhanced by glucose stimulation (Figures S1A and S1B).
Together, these data suggest that LXR was not involved in the
glucose-mediated SREBP signaling pathway.
Collectively, these data demonstrate that glucose availability
constrains SREBP activity by controlling the levels of SCAP.
Glucose Promotes SCAP N-glycosylation and Enhances
Its Stability
To explore the mechanisms of how glucose enhances SCAP
protein levels and activates SREBP, the intermediate metabolite,
pyruvate or lactate of the glycolysis pathway, or N-acetylglucos-
amine (GlcNAc) of the hexosamine biosynthetic pathway (HBP)
(Figure 2A) was added to GBM U87 cells in glucose- and ste-
rol-free medium, respectively. The data showed that GlcNAc
was as effective as glucose at enhancing SCAP protein levels
and promoting SREBP-1 cleavage, while pyruvate and lactate
had no effect (Figure 2B). Upon exposure of cells to an inhibitor
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Figure 1. Glucose Activates SREBPs via Upregulation of SCAP
(A) Western blot analysis of U87 cells cultured in serum-free media with or without glucose (5 mM) in the presence or absence of sterols (10 mg/ml 25-hy-
droxycholesterol and 10 mg/ml cholesterol) for 12 hr.
(B and C) Western blot analysis of U87 cells cultured in serum-free media with different dose of glucose for 12 hr (B) or stimulated with 5 mM glucose at indicated
times (C).
(D and E) Confocal microscopy images show GFP-SREBP-1 (green), which was derived from a cDNA lacking the exon 1 of SREBP-1 (encodes the identical aa
sequence between SREBP-1a and -1c) (D) or endogenous SREBP-1 (E, red) subcellular localization in U87 cells cultured in serum-free media with or without
glucose (Gluc) for 12 hr. The nuclei were stained by DAPI (blue). The scale bars represent 10 mm. The nucleus intensity of GFP-SREBP-1 (D) or endogenous
SREBP-1 (red) (E) was quantified over 30 cells by using ImageJ. The red lines in the quantification graphs show mean ± SEM (n = 30). The significance was
determined by an unpaired Student’s t test.
(F) Western blot analysis of membrane and nuclear extracts from U87 cells cultured in serum-free media with or without glucose (5 mM) for 12 hr.
(G and H) Western blot analysis of membrane, nuclear extracts, or total cell lysates from HEK293T cells co-transfected with GFP-SCAP or GFP vector and full
length (FL) FLAG-SREBP-1a, -1c, or HA-SREBP-2 plasmids (G) or from U87 cells after knock down of SCAP in comparison with shRNA control (shCtrl) in serum-
free media with or without glucose (5 mM) for 12 hr (H) (precursor of SREBPs, P; N terminus of SREBP-1, N; and C terminus of SREBP-2, C).
See also Figure S1.of HBP (azaserine, AZA) or to an inhibitor of N-glycan synthesis
(tunicamycin, Tuni), both SCAP protein levels and SREBP-1
cleavage were reduced, while an inhibitor of O-glycosylation
(BADGP) had no effect (Figures 2C and S2A–S2D). Immunofluo-
rescence imaging showed that glucose-induced Golgi and
nuclear translocation of SREBP-1 were largely blocked by AZA
and Tuni (Figures 2D and S2E). As expected, the addition of
GlcNAc restored AZA treatment-reduced SCAP protein levelsCaand SREBP-1 and SREBP-2 cleavages in U87 cells (Figure S2F).
These data suggest that the effects of glucose on SCAP
and SREBP were likely mediated by an induction of protein
N-glycosylation.
Nohturfft et al. (1998) showed that SCAP protein carries
three N-linked oligosaccharides at asparagine (N) positions
N263, N590, and N641 and mutations of one or two of these
asparagines had no apparent effect on the function of SCAP.ncer Cell 28, 569–581, November 9, 2015 ª2015 Elsevier Inc. 571
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Figure 2. Glucose Promotes SCAP N-glycosylation and Enhances Its Stability
(A) Schematic model shows the glucose metabolism divided into glycolysis, de novo lipid synthesis, oxidative pentose phosphate pathway (PPP), and hexos-
amine synthesis pathway (HBP) for glycosylation modification. The key enzymes controlling HBP and glycosylation modifications and their specific inhibitors are
shown in the scheme (pyruvate, Pyr; lactate, Lac; TCA; fructose-6-phosphate, Fruc-6-P; GlcNAc; AZA; Tuni; fructose-6-phosphate amidotransferase, GFAT;
dolichyl-phosphate, UDP-GlcNAc, GlcNAc-1-P transferase, DPAGT1; and O-glycosylation transferase, OGT).
(B and C) Western blot analysis of U87 cell lysates, which were derived from cells cultured in serum-free media with or without glucose (5 mM), pyruvate (10 mM),
lactate (10 mM), or GlcNAc (20 mM) (B) or in combination with AZA (100 mM), Tuni (1 mg/ml), or BADGP (1 mM) for 12 hr (C).
(D) Confocal microscopy images of SREBP-1 subcellular localization in relation with the Golgi protein marker Giantin and nuclear DAPI staining in U87 cells with
same treatment procedure as (C). The scale bars represent 10 mm.
(E) Western blot analysis of cell membrane fractions for protease-protected N-glycosylation fragment (aa 540–707) of SCAP (upper) or total GFP-SCAP protein
levels (lower) from HEK293T cells transiently transfected with GFP-SCAP for 24 hr and then cultured in serum-free media with or without glucose (5 mM) or
GlcNAc (20 mM) for another 12 hr. The numbers on the left side of the blot indicate the number of N-glycosylation on SCAP protein (upper) (Nohturfft et al., 1998).
For details, please see Supplemental Information.
(F and G) Western blot analysis of SCAP N-glycosylation (upper) or GFP-SCAP protein levels (lower) from HEK293T cells transiently transfected with GFP-SCAP
for 24 hr and then cultured in serum-freemedia with or without GlcNAc (20mM) or glucose (5mM) in the presence or absence of AZA (100 mM) (F) or with or without
glucose in combination with Tuni (1 mg/ml) (G) for 12 hr.
(H) Western blot analysis of cell membrane fractions fromU87 cells cultured in serum-freemedia with or without glucose (5mM) in combination with Tuni (1 mg/ml)
and protease inhibitor E64D (10 mg/ml)/Pepstatin A (10 mg/ml)/Leupeptin (10 mg/ml) or proteasome inhibitor MG132 (50 mM) for 12 hr.
(I) Western blot analysis of cell membrane fractions from U87 cells cultured in serum-free media with or without glucose (5 mM) in the presence or absence of
MG132 (50 mM) for 6 hr.
(J and K) Western blot analysis of cell membrane fractions from HEK293T cells transfected with indicated amounts of plasmid expressing the wild-type GFP-
SCAP (NNN) or mutant GFP-SCAP (QQQ) for 24 hr (J), then treated with or without MG132 (50 mM) for another 4 hr (K). The levels of GFP-SCAP-NNN or -QQQ
were quantified by ImageJ and normalized with PDI. The results are shown asmean ± SD (n = 3). The significance was determined by an unpaired Student’s t test
(*p < 0.01).
See also Figure S2.
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However, a version of SCAP with all three asparagines mutated
to glutamine (NNN to QQQ) could not be detected, suggesting
that N-glycosylation is important for the stability of SCAP (Noh-
turfft et al., 1998). Therefore, we asked whether glucose might
control the levels of SCAP by affecting its glycosylation. Further-
more, the role for N-glycosylation in SCAP/SREBP function has
not been extensively explored.
We adopted the approach of Nohturfft et al. (1998) and exam-
ined the effects of glucose on SCAP N-glycosylation in HEK293T
cells and CHO cells. SCAP contains a luminal region (amino acid,
aa, 540–707) with two N-glycosylation sites that is protected
from proteolysis when intact membranes are treated with trypsin
(Nohturfft et al., 1998). This luminal fragment has a molecular
weight of 30 kDa that is small enough to allow the resolution
of individual glycosylated variants of SCAP by SDS-PAGE (Fig-
ures 2E, upper, and S2G). Glucose deprivation for 12 hr resulted
in two weaker bands that correspond to SCAP fragments car-
rying one or two oligosaccharides in HEK293T cells expressing
GFP-SCAP (Figure 2E, upper), indicating that the level of SCAP
N-glycosylation was decreased under a low glucose condition
that was correlated with reduced total GFP-SCAP protein (Fig-
ures 2E, lower, and S2H). Removal of the oligosaccharides by
treatment with endoglycosidase (PNGase) reduced the apparent
molecular weight to the unglycosylated form of SCAP (Nohturfft
et al., 1998). Notably, in the presence of glucose, high amounts
of fully glycosylated forms of SCAP and total GFP-SCAP
protein were detected (Figures 2E, S2G, and S2H), which were
associated with elevated SREBP activation (Figures 1F, 1G,
and S1G). Supplementing the culture medium with GlcNAc
enhanced SCAP glycosylation and increased the total GFP-
SCAP protein to a level similar to that found upon glucose treat-
ment (Figure 2E). Furthermore, AZA or Tuni treatment blocked
glucose-promoted SCAP N-glycosylation and reduced GFP-
SCAP levels in HEK293 cells and endogenous SCAP levels in
CHO cells (Figures 2F, 2G, S2G, and S2H), and the addition of
GlcNAc restored AZA treatment-mediated reduction of SCAP
N-glycosylation and total GFP-SCAP protein to levels similar to
cells exposed to glucose supplement alone (Figure 2F). In
GBM cells treated with Tuni, the endogenous SCAP protein level
was reduced (Figures 2H and S2C). Co-treatment with MG132, a
proteasome inhibitor, but not protease inhibitors (combination of
E64d, pepstatin A, and leupeptin), restored the SCAPprotein to a
level similar to that when cells were exposed to glucose alone
(Figures 2H and 2I). Taken together, these data demonstrate
that glucose deprivation-led reduction of SCAP protein levels
is caused by proteasome-dependent degradation.
To examine the effect of N-glycosylation on SCAP stability, we
generated a mutant form of SCAP by replacing all three aspara-
gines (N263, N590, and N641) with glutamines (NNN to QQQ).
We added a GFP tag to the N-terminal end of SCAP and used
a strong CMV promoter to drive its expression in HEK293T cells.
This enabled us to produce ameasurable amount of GFP-SCAP-
QQQ protein, overcoming the problem Nohturfft et al. (1998)
faced. Compared with the wild-type protein (GFP-SCAP-NNN),
lower levels of GFP-SCAP-QQQ were detected (Figure 2J), sug-
gesting that the unglycosylated SCAP proteins are less stable
and presumably are more susceptible to proteasomal degrada-
tion. Indeed, treatment of cells with MG132 significantly restored
GFP-SCAP-QQQ protein levels (Figure 2K).CaGlucose-Mediated Glycosylation Promotes SCAP
Trafficking to the Golgi Leading to SREBP Activation
Wewonderedwhether N-glycosylation altered the association of
SCAP with Insig and thereby promoted SCAP/SREBP trafficking
to the Golgi in the absence of sterols. To address this, HEK293T
cells were co-transfected with Myc-Insig-1 and GFP-SCAP or
GFP-vector to determine their interaction in response to glucose
and Tuni treatment. We found that glucose treatment reduced
the association of GFP-SCAP with Myc-Insig-1 compared with
a glucose-deprived condition (Figure 3A). Further, blocking
N-glycosylation by Tuni restored the binding of GFP-SCAP to
Myc-Insig-1 (Figure 3A). These data suggest that N-glycosyla-
tion modification by glucose reduced the binding of SCAP to
Insig-1. To test if this affected the SCAP/SREBP trafficking to
the Golgi, the subcellular distribution of GFP-SCAP was exam-
ined by confocal microscopy. The data show that glucose stim-
ulation promoted the GFP-SCAP trafficking to the Golgi, which
was blocked by inhibition of N-glycosylation with Tuni (Figures
3B and S3A).
Data with transient expression of GFP-SCAP-QQQ mutant
and Myc-Insig-1 in HEK293T cells further supported the notion
that N-glycosylation reduces SCAP binding to Insig-1 and sub-
sequent SCAP/SREBP trafficking to the Golgi. We found that
GFP-SCAP-QQQ displayed stronger association with Myc-
Insig-1 compared with GFP-SCAP-NNN (Figure 3C). While
GFP-SCAP-NNN promoted trafficking of FLAG-SREBP-1c to
the Golgi and subsequent translocation to the nucleus, the
GFP-SCAP-QQQ mutant failed to do so (Figures 3D and S3B).
The contribution of individual N-glycosylation sites to SCAP
function and trafficking was further investigated in HEK293T and
U87 cells expressing the GFP-SCAP protein harboring single,
double, or triple mutations. Our data showed that none of the sin-
gle or doublemutations in SCAP impaired the trafficking and acti-
vation of FLAG-SERBP-1c in response to glucose stimulation
(Figures 3E–3G, S3C, and S3D). These data were consistent
with the early studies by the Brown and Goldstein Laboratory,
which demonstrated thatmutations of one or twoN-glycosylation
sitesproducednegligibleeffectsonSREBP-2activation (Nohturfft
et al., 1998). Interestingly, we found that the triple mutant GFP-
SCAP-QQQwasunable to traffic to theGolgi and failed to activate
epitope-tagged SREBP-1a, -1c, and SREBP-2 (Figures 3F, 3G,
S3C, and S3E–S3G). Thus, even though maintenance of a single
glycosylation site onSCAPappeared tobe sufficient for its biolog-
ical function (Nohturfft et al., 1998), complete abolition of all glyco-
sylation sites on SCAP disrupted the exit pathway for the SCAP/
SREBP complex from ER to the Golgi.
Elegant studies by Brown and Goldstein Laboratory estab-
lished that sterols are critical factors in the regulation of SCAP
trafficking andSREBP activation (Goldstein et al., 2006).We con-
ducted similar studies and found that the incubation of cells with
sterols could block glucose-mediated SCAP trafficking and
SREBP-1 nuclear translocation (Figures S3H and S3I). Overex-
pressing Myc-Insig-1 or increasing sterol concentration reduced
glucose-mediated SREBP-1 activation (Figures S3J and S3K).
While these data are consistent with the early work of Brown
and Goldstein Laboratory, the present findings suggest that
glucose is indispensable for SCAP/SREBP trafficking and func-
tion. Our data support that N-glycosylation relieves SCAP asso-
ciationwith Insig, leading to SCAP/SREBP trafficking to theGolgincer Cell 28, 569–581, November 9, 2015 ª2015 Elsevier Inc. 573
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Figure 3. N-glycosylation Promotes SCAP Trafficking to the Golgi Leading to SREBP-1 Activation
(A) Total (Input) or immunoprecipitated (IP) lysates from HEK293T cells transfected with GFP-SCAP or GFP vector together with Myc-Insig-1 without or with
glucose (5 mM) stimulation in the presence or absence of Tuni (1 mg/ml) for 12 hr were immunoblotted using the indicated antibodies.
(B) Confocal microscopy images showGFP-SCAP trafficking related to the Golgi marker Giantin in response to glucose (5mM) in the presence or absence of Tuni
(1 mg/ml) in U87 cells for 12 hr. The scale bars represent 10 mm.
(C) Immunoblot analysis of total or immunoprecipitated lysates from HEK293T cells transfected with wild-type GFP-SCAP (NNN) or mutant GFP-SCAP (QQQ)
together with Myc-Insig-1 in response to glucose (5 mM) for 12 hr using the indicated antibodies.
(D) Confocal microscopy images show SCAP and SREBP-1 trafficking in U87 cells transfected with wild-type GFP-SCAP (NNN) or mutant GFP-SCAP (QQQ)
together with FLAG-SREBP-1c (full length, FL) in response to glucose (5 mM) for 12 hr. The scale bars represent 10 mm. The nucleus intensity of FLAG-SREBP-1c
was quantified over 30 cells by using ImageJ. The results are shown as mean ± SEM (n = 30). The significance was determined by an unpaired Student’s t test.
(E) Western blot analysis of the N-glycosylation levels of SCAPmutant in HEK293T cells transfected with different mutant of GFP-SCAP in comparison with wild-
type (NNN).
(F) Confocal microscopy images show the trafficking of different SCAPmutants in U87 cells transfectedwith wild-type (NNN) or differentmutant GFP-SCAP under
glucose (5 mM) treatment in serum-free media. The scale bars represent 10 mm.
(G) Western blot analysis of membranes and nuclear extracts from HEK293T cells transfected with wild-type or different mutant GFP-SCAP together with FLAG-
SREBP-1c (full length) in response to glucose (5 mM) stimulation in serum-free media.
See also Figure S3.and subsequent SREBP activation; and sterols could antagonize
glucose function on SCAP trafficking and SREBP activation.
EGFR Signaling Activates SREBP-1 by Enhancing the
Glucose Uptake, SCAP Protein Levels, and N-
glycosylation
EGFR signaling has been shown to enhance glucose uptake and
activate SREBP-1 (Babic et al., 2013; Guo et al., 2009a, 2009b).574 Cancer Cell 28, 569–581, November 9, 2015 ª2015 Elsevier Inc.Based on our observation that SREBP activation in sterol-
deprived conditions was fully dependent on glucose (Figure 1),
we tested whether EGFR-mediated SREBP-1 activation also
required glucose. As shown in Figure 4A, EGF stimulation was
unable to promote the nuclear translocation of SREBP-1 in the
absence of glucose and the addition of glucose could restore
EGF-mediated SREBP-1 nuclear translocation. Western blotting
showed that EGF stimulation had no effect onSREBP-1 cleavage
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SREBP-1 DAPI Figure 4. EGFR Signaling via Promoting
Glucose Uptake Upregulates SCAP and
Activates SREBP-1
(A and B) Confocal microscopy images of
SREBP-1 subcellular distribution (A) or western
blot analysis of SREBP-1 cleavage (B) in U87/
EGFR cells in response to EGF (50 ng/ml) in the
presence or absence of glucose (5 mM) for 12 hr.
The scale bars represent 20 mm. The SREBP-1
nucleus intensity was quantified over 30 cells by
using ImageJ. The results are shown as mean ±
SEM (n = 30). The significance was determined by
an unpaired Student’s t test.
(C) Glucose uptake analysis of U87/EGFR cells in
response to EGF (50 ng/ml) by using 14C-glucose
isotope. The results are shown as mean ± SD
(n = 3). The significance was determined by an
unpaired student t test.
(D) Western blot analysis of cell membrane and
nuclear extracts from U87/EGFR cells in response
to EGF (50 ng/ml) stimulation in the presence or
absence of glucose (5 mM) for 12 hr.
(E) Western blot analysis of U87/EGFR cells after
knock down of SCAP in comparison with shRNA
control (shCtrl) in response to EGF (50 ng/ml)
stimulation in the presence of glucose (5 mM)
for 12 hr.
See also Figure S4.in glucose-free media, even though the EGFR-PI3K-Akt-mTOR
signaling pathway was strongly activated as evidenced by the
upregulation of p-EGFR, p-Akt, and p-S6 (Figures 4B and S4A).
In contrast, EGF stimulation in the presence of glucose promoted
the cleavage of SREBP-1 (Figures 4B and S4A).
Using 14C-glucose radioisotopemeasurements, we found that
EGF stimulation led to the significant increase of glucose uptake
in U87/EGFR cells (Figure 4C). While EGF stimulation did not
appear to affect the SCAP protein level in the absence of
glucose, the additive effect of glucose and EGF-dependent
enhancement of SCAP expression was observed (Figures 4D
and S4A). Moreover, the EGF-induced changes in SCAP expres-
sion were correlated with SREBP-1 activation, as reflected by
the increased appearance of the SREBP-1 N-terminal fragment
in the nuclear fraction (Figures 4D and S4A). Furthermore, the in-
crease in glucose uptake by insulin in HepG2 cells also upregu-
lated SCAP protein and activated SREBP-1 (Figures S4B andCancer Cell 28, 569–581,S4C), suggesting that the activation
of the glucose-SCAP-SREBP signaling
pathway could be induced by various
other growth factors. We then knocked
down the expression of SCAP in U87/
EGFR cells in order to examine whether
the effect of EGF on SREBP-1 activation
was mediated by the glucose-SCAP
axis. As shown in Figure 4E, knock down
of SCAP completely abolished EGF-
mediated activation of SREBP-1.
Inhibition of the HBP pathway by
AZA or suppression of N-glycosylation
by Tuni blocked EGF-mediated nucleartranslocation of SREBP-1, whereas the O-glycosylation inhibitor
BADGP treatment failed to do so (Figure 5A). Western blotting
showed that AZA or Tuni treatment blocked EGFR signaling-
dependent increase in SREBP-1 cleavage, whereas no changes
were observed by BADGP treatment (Figure 5B). Moreover,
EGF-mediated upregulation of SCAP was reduced by AZA or
Tuni treatment, but not by the BADGP treatment (Figure 5B).
We incubated U87/EGFR cells with 14C-glucose and measured
isotope labeled lipid products and found that AZA or Tuni treat-
ment significantly reduced EGFR signaling-dependent increase
in de novo lipid synthesis (Figure 5C). These results demonstrate
that N-glycosylation was a key mediator for EGFR signaling-
mediated increase in SCAP level and subsequent activation of
SREBP-1.
We then assessed the effect of EGF stimulation on SCAP
glycosylation. Stimulation of cells with EGF led to the increase
of the total and the N-glycosylated GFP-SCAP protein whenNovember 9, 2015 ª2015 Elsevier Inc. 575
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Figure 5. EGFR Signaling Activates SREBP-1 via Upregulation of SCAP N-glycosylation
(A and B) Confocal microscopy images of SREBP-1 translocation (A) or western blot analysis of SCAP levels and SREBP-1 cleavage (B) in U87/EGFR cells
cultured in serum-free media in response to EGF (50 ng/ml) in the presence or absence of AZA (100 mM), Tuni (1 mg/ml), or BADGP (1 mM) with glucose (5 mM)
for 12 hr. The scale bars represent 20 mm. The SREBP-1 nucleus intensity was quantified over 30 cells by using ImageJ. The results are shown as mean ± SEM
(n = 30). The significance was determined by an unpaired Student’s t test.
(C) De novo lipid synthesis analysis in U87/EGFR cells cultured in serum-free media treated with or without EGF (50 ng/ml) in combination with AZA (100 mM) or
Tuni (1 mg/ml) for 12 hr, then adding 0.5 mCi 14C-labeled glucose for 2 hr, followed by lipid extraction and analysis by scintillation counter. The results are presented
as mean ± SD (n = 3). The significance was determined by an unpaired student t test (*p < 0.05 and **p < 0.01).
(D) Western blot analysis of total protein (upper) and N-glycosylation levels (lower) of GFP-SCAP and SREBP-1 nuclear form (upper) in LN229/EGFR cells
transiently expressing GFP-SCAP after the stimulation of EGF (50 ng/ml) in the presence or absence of Tuni (1 mg/ml) for 12 hr.
(E) Western blot analysis of U87/EGFR cells transfected with GFP, wild-type GFP-SCAP (NNN), or triple mutant GFP-SCAP (QQQ) after the stimulation of EGF
(50 ng/ml) in serum-free media for 12 hr.compared with control and both were blocked by Tuni (Fig-
ure 5D). In correlation, EGF stimulation also upregulated
SREBP-1 activity, which was inhibited by Tuni (Figure 5D, up-
per). Similar to the studies in Figure 3G, we measured the effect
of EGF onSREBP-1 function in U87/EGFR cells expressingGFP-
SCAP-NNN or GFP-SCAP-QQQ. We found that cells expressing
GFP-SCAP-NNN showed enhanced SREBP-1 activation in
response to EGF stimulation, whereas cells expressing GFP-
SCAP-QQQ showed reduced SREBP-1 activation even below
the levels observed with cells expressing GFP alone (as control)
(Figure 5E). Interestingly, biochemical studies showed that the
other signaling components for EGFR, e.g., p-EGFR, p-AKT,
and p-S6, were not affected by overexpression of either GFP-
SCAP-NNN or GFP-SCAP-QQQ in U87/EGFR cells (Figure 5E).
Taken together, our data show that EGFR-dependent SREBP-1
activation is mediated by upregulation of SCAP and its N-glyco-
sylation through enhancing glucose uptake.576 Cancer Cell 28, 569–581, November 9, 2015 ª2015 Elsevier Inc.Impairment of SCAP N-glycosylation Suppresses GBM
Tumor Growth
To determine the effect of EGFR on SCAP/SREBP-1 function in
tumorigenesis, we employed a cell culture model with stable
expression of EGFRvIII, a constitutively active form of EGFR
with enhanced activation of PI3K-Akt signaling that leads to
aggressive tumorigenesis (Guo et al., 2009b; Huang et al.,
1997). Western blot revealed that U87/EGFRvIII cells displayed
elevated SCAP protein levels and enhanced SREBP-1 activation
associated with upregulated p-Akt and p-S6 levels (Figure 6A).
Based on this observation, we asked whether EGFRvIII-medi-
ated tumorigenesis is mediated by enhanced SCAP expression
and its glycosylation.
We established a stableU87/EGFRvIII cell linewith knock down
of SCAP (U87/EGFRvIII-shSCAP). Western blotting showed that
knock down of SCAP reduced SREBP-1 activation (Figure 6B)
and which significantly reduced tumor growth in mouse flanks
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Figure 6. Impairment of SCAP N-glycosylation Suppresses Tumor Growth and Significantly Prolongs Overall Survival of GBM-Bearing Mice
(A) Western blot analysis of SCAP levels and SREBP-1 cleavage in U87 versus U87-EGFRvIII cells.
(B–D) The effects of shRNA-mediated knock down of SCAP in U87/EGFRvIII cells analyzed by western blot (B), subcutaneous tumor growth (1 3 106 cells/
mouse), which are shown as mean ± SEM (n = 8) (C), or overall survival of intracranial tumor bearing-mouse (1 3 105 cells/mouse) assessed by Kaplan-Meier
analysis (D).
(E–H) The effects of wild-type GFP-SCAP (NNN) or mutant GFP-SCAP (QQQ) compared with the control GFP expression in U87/EGFRvIII cells analyzed by
western blot (E), subcutaneous tumor growth (1 3 106 cells/mouse), which are shown as mean ± SEM (n = 5) (F), luminescence imaging of intracranial
tumor (1 3 105 cells/mouse) at day 14 after implantation, which are shown as mean ± SEM (n = 7) (G), or GBM bearing-mouse overall survival assessed by
Kaplan-Meier analysis (H). The significance was determined by an unpaired Student’s t test (*p < 0.05 and **p < 0.01). The survival was analyzed by log
rank test.comparedwith theshort hairpin (sh)RNAcontrol group (Figure6C).
To assess the potential of thesemodifiedGBMcells to formortho-
topic tumors, shSCAP or shControl cells were implanted into
mouse brain. A Kaplan-Meier plot showed that reducing the
SCAP level significantly prolonged the overall survival of GBM-
bearing mice (Figure 6D).
We next examined whether the impairment of SCAP N-glyco-
sylation had any effect on GBM tumorigenesis. For this purpose,
GFP-SCAP-NNN, GFP-SCAP-QQQ, or GFP (as control) was
transiently expressed in U87/EGFRvIII cells. The data showed
that the expression of GFP-SCAP-NNN enhanced, whereas
GFP-SCAP-QQQ reduced SREBP-1 activation, compared with
cells transfected with GFP (Figure 6E), suggesting that GFP-
SCAP-QQQ had a dominant negative effect on SREBP-1 activa-
tion. Next, these transfected cells were implanted into mouse
flanks. As shown in Figure 6F, GFP-SCAP-NNN expression pro-Camoted GBM tumor growth compared with the GFP control,
whereas GFP-SCAP-QQQ expression significantly reduced the
GBM tumor growth.
Finally, to determine the effect of SCAP N-glycosylation on
GBM intracranial tumor growth, we used a U87/EGFRvIII cell
line with stable expression of luciferase, which allows the visual-
ization of a tumor in mouse brain using luminescence imaging
(Wojton et al., 2013). The data showed that the expression of
GFP-SCAP-NNN promoted tumor growth, whereas the expres-
sion of GFP-SCAP-QQQ significantly reduced tumor growth
(Figure 6G). Moreover, overexpression of GFP-SCAP-NNN
reduced the overall survival of GBM-bearing mice (Figure 6H).
Inversely, impairment of SCAP N-glycosylation significantly pro-
longed the overall survival of mice (Figure 6H). Collectively, these
data demonstrate that N-glycosylation on SCAP is a critical fac-
tor for EGFRvIII-induced GBM tumorigenesis.ncer Cell 28, 569–581, November 9, 2015 ª2015 Elsevier Inc. 577
Figure 7. Schematic Diagram Illustrating EGFR Signaling via Enhancing Glucose Uptake Promotes SCAP N-glycosylation Leading to
SREBP-1 Activation
(A) Signaling cascade for EGFR stimulation and glucose uptake to SCAP N-glycosylation and SREBP-1 activation.
(B) Without glucose, unglycosylated SCAP binds to Insig, leading to retention of SREBP in the ER. Under this condition, changes in sterol level are insufficient to
trigger exit of the SCAP/SREBP complex from the ER. In the presence of glucose, N-glycosylation of SCAP leads to increased stability of SCAP and its
dissociation from Insig. Thus, the SCAP/SREBP complex can traffic to the Golgi, resulting in SREBP cleavage and its nuclear function. The sterols block glucose-
mediated SCAP/SREBP trafficking and the subsequent SREBP activation. The elevated EGFR signaling causes increased glucose uptake and SCAP/SREBP
activation to promote tumor growth.DISCUSSION
Malignant cells, in general, have high rates of de novo lipid syn-
thesis (Currie et al., 2013; Guo et al., 2013; Menendez and Lupu,
2007). Since solid tumors often reside in an environment with
fluctuant nutrient supply (Ackerman and Simon, 2014; Gullino
et al., 1967; Hirayama et al., 2009), they must develop adaptive
mechanisms to preserve energy for maintenance of tumor cell
survival under conditions of low glucose supply. Proper gauging
of glucose levels and lipid synthesis is not only critical for tumor
growth and survival, but also for normal cell function under stress
conditions. In this study, we demonstrate that SCAP acts as a
key glucose-responsive protein to orchestrate fuel availability
and sterol levels for control of SREBP function in lipid synthesis.
We show that glucose controls N-glycosylation of SCAP, which
is indispensable for SCAP/SREBP trafficking from ER to the
Golgi and for the nuclear activation of SREBPs (Figure 7). This
finding renovates our current understanding of the regulation
of SREBP function in physiology and patho-physiology. Elegant
studies by Brown andGoldstein demonstrated that sterols act as578 Cancer Cell 28, 569–581, November 9, 2015 ª2015 Elsevier Inc.negative regulators for SCAP/SREBP trafficking (Goldstein et al.,
2006), and an5% decrease of cholesterol in the ERmembrane
is sufficient to trigger the activation of SREBP (Radhakrishnan
et al., 2008). Such a tight regulation mechanism necessitates
the participation of additional cellular factors to coordinate
with sterols for the fine tuning of SREBP function in normal and
patho-physiological conditions. Our study unravels the impor-
tant function of glucose in controlling lipid metabolism in tumor-
igenesis, linking EGFR signaling to glucose uptake and SCAP/
SREBP activation (Figure 7).
Activation of SREBP relies on SCAP-escorted trafficking from
ER to the Golgi (Goldstein et al., 2006). Sterols serve as negative
regulators enhancing SCAP binding to Insig to retain the SCAP/
SREBP complex in ER membrane (Goldstein et al., 2006). In this
study, we show that in glucose-deficient conditions, removal of
sterols was unable to relieve SCAP binding to Insig-1 and trigger
exit of SCAP/SREBP from ER. A supplement of glucose pro-
moted SCAP N-glycosylation and SCAP/SREBP trafficking to
the Golgi and consequent SREBP activation. We show that the
interaction between SCAP and Insig-1 is reduced when SCAP
is glycosylated. Studies by Brown and Goldstein have shown
that Insig is a sterol sensor that negatively regulates SCAP inter-
action with SREBP (Goldstein et al., 2006). Our data are consis-
tent with their idea, as we show that even in the presence of
glucose, sterol still exerts its control of SCAP/SREBP trafficking
and subsequent SREBP activation. Thus, glucose functions as a
prerequisite activator for control of SCAP trafficking and SREBP
activation. Since sterol can still block SCAP/SREBP signaling
complex, future studies will be required to examine how glucose
communicates with sterol in orchestrating the crosstalk between
energy supply and lipid metabolism in physiology and cancer
biology.
There are three N-glycosylation sites on SCAP, one located
in loop 1 (N263) and two in loop 7 (N590 and N641) and both
loops reside in the inner lumen of ER (Nohturfft et al., 1998).
Interestingly, mutation in any one or two sites of N-glycosyla-
tion was unable to affect SCAP trafficking and SREBP function.
This observation was consistent with a previous report by
Nohturfft et al. (1998), who demonstrated that, as long as one
N-glycosylation site is present on SCAP, its control of
SREBP-2 is unperturbed. Here, we tested the hypothesis that
the presence of any single glycosylation site on SCAP is suffi-
cient for SCAP/SREBP trafficking and activation. We found that
even though presence of a single glycosylation site on SCAP
appeared to be sufficient for its biological function, complete
abolition of all glycosylation sites on SCAP disrupted the exit
pathway for the SCAP/SREBP complex from ER to the Golgi.
This further supports the notion that specific recognition of
the glycosylation motif may provide a mechanism for modula-
tion of the Insig/SCAP/SREBP interaction. Clearly, identification
of the binding motif for Insig or SCAP for N-linked oligosaccha-
ride will require further studies.
Our previous studies revealed that SREBP-1 is activated by
the EGFR-PI3K-Akt signaling pathway, but mTORC1 seems
not involved (Guo et al., 2009b, 2011). Studies by other investi-
gators reported that PI3K-Akt-mTORC1 signaling regulates
SREBP-1 activation (Du et al., 2006; Porstmann et al., 2005;
Yecies et al., 2011). Therefore, the mechanisms that underlie
the oncogenic signaling to SREBP-1 function remain unclear.
In the present study, we show that in the absence of glucose,
EGF cannot activate SREBP-1, even though other downstream
signaling components (e.g., p-Akt, p-S6) remain upregulated.
This suggests that EGFR-mediated control of SREBP-1 is fully
dependent on glucose. We also examined mTORC1 activity by
checking its downstream effectors p-S6 and total S6 levels in
the absence or presence of serum. The data show that the levels
of p-S6 and total S6 were not significantly changed by glucose
withdrawal within a 12 hr time window. In contrast, the levels
of SCAP and SREBP-1 and SREBP-2 activation were reduced.
Moreover, in the absence of glucose, even a growth factor
(EGF or insulin) strongly activatedmTORC1, but failed to activate
SCAP/SREBP signaling. Taken together, these data demon-
strate that glucose, not mTORC1, plays a critical role in regu-
lating SCAP/SREBP signaling.
Our study revealed that EGFR signaling via promoting glucose
uptake enhances SCAP N-glycosylation and its protein levels to
activate SREBP-1. This finding provides a plausible explanation
for the conundrum faced by the tumor cells: Under rich nutrient
environment, oncogenic signaling via hijacking glucose import-CaSCAP N-glycosylation-SREBP-1 activation metabolic pathway
enhances lipogenesis and promotes rapid tumor growth. Once
the glucose level drops, SCAP losesN-glycosylation and discon-
nects oncogenic signaling with SREBP-1, leading to reduced
lipogenesis and thereby preserving limited energy sources
for tumor cell survival. These data demonstrate the plasticity
and survival capability of tumor cells in facing harsh nutrient
microenvironment.
Complete understanding of the molecular mechanisms of
SCAP/SREBP trafficking and its relationship to fuel supply and
growth signaling may help design effective therapeutic strate-
gies to target lipid metabolism in cancer and other metabolic
syndromes.
EXPERIMENTAL PROCEDURES
More detailed procedures were described in the Supplemental Information.
Plasmids
GFP-SCAP wild-type plasmid is a gift from Dr. Peter Espenshade. Original
plasmids for SCAPmutants were provided by Drs. Nohturfft, Brown, andGold-
stein (Nohturfft et al., 1998). The 23 HA-SREBP-2 (full length) plasmid is a gift
from Dr. John Shyy. Adenovirus expressing GFP-SREBP-1 (full length) was
produced and amplified as described (Dif et al., 2006).
Cell Culture and Transfection
U87, U87EGFR, U87EGFRvIII (Guo et al., 2009b), HEK293T, U87EGFRvIII-luc,
and other cancer cell lines were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Cellgro) supplemented with 5% HyClone fetal bovine serum
(FBS; Thermo Scientific). All cell cultures were supplemented with 1% peni-
cillin/streptomycin/glutamine and cells incubated at 5% CO2 at 37
C. Trans-
fection of plasmids was performed using X-tremeGENE HP DNA Transfection
Reagent (Roche) following the manufacturer’s instructions.
Co-immunoprecipitation
Co-immunoprecipitation assay was performed as described previously (Yang
et al., 2002).
Preparation of Cell Membrane Fractions and Nuclear Extracts
Cell membrane and nuclear fractions were isolated as described previously
(Nohturfft et al., 1998).
Detection of SCAP N-glycosylation
The detection of SCAP N-glycosylation was performed according to the
method described previously (Nohturfft et al., 1998).
Xenograft Mouse Model and Mouse Survival
GBMcells (13 106 cells) were implanted into the flank of athymic nu/nu female
mice (6–8 weeks old) subcutaneously. Mice were sacrificed by euthanasia
when tumor size reached the limitation and tumors were isolated and weighed.
For intracranial xenograft models, 1 3 105 GBM cells in 4 ml of PBS were
stereotactically implanted into mouse brain. Mice were then observed until
they became moribund, at which point they were sacrificed. All animal proce-
dures were approved by the Subcommittee on Research Animal Care at The
Ohio State University Medical Center.
Mouse Luminescence Imaging
Mice implanted with GBM cells expressing luciferase were injected with lucif-
erin (Perkin Elmer) solution (15 mg/ml in PBS and dose of 150 mg/kg) by an
intraperitoneal route for about 5–15 min. Mice were placed into a clear Plexi-
glas anesthesia box (2.0%–3.0% isoflurane) that allowed unimpeded visual
monitoring of the animals. Animals were then placed on non-fluorescent black
paper on the imaging platform of an IVIS Lumina II to reduce background
noise. The imaging chamber was continuously infused with 1%–1.5% of
isoflurane and the imaging platform was heated at 37C to keep the
mice warm. Animals were imaged 10 min after luciferin injection to ensurencer Cell 28, 569–581, November 9, 2015 ª2015 Elsevier Inc. 579
consistent photon flux. The imaging experiments were conducted at The Ohio
State University (OSU) Small Animal Imaging Core.
Statistical Analysis
Statistical analyses were performed by Excel or GraphPad Prism5. All data are
analyzed by two-tailed t test as well as by ANOVA as appropriate and p < 0.05
was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2015.09.021.
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